优化，成就与众不同 Optimization Makes Differences 证券代码：688293 证券简称：奥浦迈 上海奥浦迈生物科技股份有限公司 2025 年第三次临时股东大会 会议资料 二〇二五年十二月 1 三、会议按照会议通知上所列顺序审议、表决议案。 | 2025 | | 年第三次临时股东大会会议须知 3 | | --- | --- | --- | | 2025 | | 年第三次临时股东大会会议议程 6 | | 议案 | 1： | 8 | | 《关于变更公司注册资本、取消监事会、修订<公司章程>并办理工商变更登记的议案》..8 | | | | 议案 | 2： | 10 | | 《关于制定及修订公司部分治理制度的议案》 10 | | | 优化，成就与众不同 Optimization Makes Differences 上海奥浦迈生物科技股份有限公司 2025 年第三次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》以及《上海奥浦迈生物科技股份有限公司章程》《上海奥 ...

Core Viewpoint - Aopu Mai's stock price has experienced fluctuations, with a current decline of 2.01% and a year-to-date increase of 59.83%, indicating volatility in the market while showing strong annual growth in revenue and profit [1][2]. Company Overview - Aopu Mai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company is located in Shanghai and specializes in cell culture products and services [1]. - The revenue composition of Aopu Mai is primarily from products (87.34%), followed by services (12.53%) and other sources (0.13%) [1]. Financial Performance - For the period from January to September 2025, Aopu Mai reported a revenue of 272 million yuan, representing a year-on-year growth of 25.79%. The net profit attributable to the parent company was 49.43 million yuan, showing an impressive increase of 81.48% year-on-year [1]. - Since its A-share listing, Aopu Mai has distributed a total of 173 million yuan in dividends [2]. Shareholder Information - As of September 30, 2025, Aopu Mai had 3,682 shareholders, an increase of 14.63% from the previous period. The average number of circulating shares per shareholder rose by 27.96% to 30,838 shares [1]. - Among the top ten circulating shareholders, notable increases were observed in holdings by institutional investors such as China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [2].

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Group 1: Company Restructuring and Financial Performance - The company is currently in the process of restructuring, having received an inquiry letter in July and completed the related responses by September. The restructuring report was revised and disclosed on November 11, 2025, and is still under review [1] - For the first three quarters of 2025, the company achieved operating revenue of 271.53 million yuan, a year-on-year increase of 25.79%. The net profit attributable to shareholders was 49.43 million yuan, up 81.48% year-on-year [9] Group 2: Gross Margin and Business Segments - The overall gross margin for the first three quarters has declined compared to 2024, primarily due to structural impacts from two business segments. The gross margin for cell culture products remains stable at 70%-71% [2] - The cell culture product segment generated revenue of 238.60 million yuan, reflecting a significant growth of 32.56% year-on-year, and remains the core revenue driver for the company [3] Group 3: Market Expansion and Client Engagement - The company is successfully engaging with multinational corporations (MNCs) in the U.S., with products being tested by several American pharmaceutical companies. There are over 10 pipelines associated with business development (BD) going overseas [5] - The company has established a U.S. research laboratory in 2024 and is considering building a production base in the U.S. to meet overseas client demands [5] Group 4: Product Pricing and Market Position - The company maintains strong customer loyalty in the antibody drug field, with long-term supply agreements that allow for differentiated pricing based on purchase volume [4] - According to a market research report, the company ranked first among domestic manufacturers of cell culture media for high-end antibody drugs in 2020, indicating a growing market share [8]

Group 1: Macro Economic Insights - Construction activity is weakening, with the construction opening rate falling to historical lows, and industrial production remains at a historically high level [5][6] - Demand in the construction sector is weak, with low apparent demand for rebar and building materials, while automobile sales are also declining [5] - Recent weeks show a mixed performance in commodity prices, with black metals and coal prices recovering, while chemical products are experiencing a decline [6] Group 2: Industry Performance - The retail sales growth rate for October 2025 shows a year-on-year increase of 2.9%, but the growth rate continues to decline, particularly in the home appliance and automotive sectors [18][19] - The white liquor industry is in a bottoming phase, with structural recovery in demand during the holiday season, while the snack food sector shows resilience due to high-frequency demand [20] - In the poultry sector, chicken prices are supported by seasonal demand, while egg prices are declining, leading to accelerated culling of laying hens [22][23] Group 3: Company Updates - Li Min Co. (002734.SZ) has seen a price increase in its manganese-based products, and a strategic partnership with BASF has been established to enhance growth potential [37][38] - Bilibili (09626.HK) reported a significant increase in Q3 revenue, driven by advertising and new game launches, maintaining a "buy" rating [41][42] - Tencent Holdings (00700.HK) continues to experience high growth in revenue and net profit, with strong performance in both new and existing games, supported by AI applications [46][48] Group 4: Investment Opportunities - The 2025 private placement market is showing signs of recovery, with a significant increase in the number of new proposals and financing scale [10][12] - The Robotaxi industry is gaining traction, with companies like Xiaoma Zhixing and Wenyan Zhixing going public, indicating growth potential in the autonomous driving sector [31] - The outdoor camping and barbecue market is expected to thrive, with companies like Guoquan focusing on expanding their product offerings in this area [34]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has shown strong revenue growth, with a 25.79% year-on-year increase in revenue for the first three quarters of 2025, reaching 272 million yuan. The net profit attributable to shareholders increased by 81.48% to 49 million yuan during the same period [6] - The cell culture product business is a key driver of revenue growth, achieving a 32.56% year-on-year increase in revenue, totaling 239 million yuan for the first three quarters of 2025 [7] - The company is expanding its overseas business, with over ten pipeline projects authorized for overseas development, which is expected to support future growth [7] Financial Performance Summary - For the first three quarters of 2025, the company reported a revenue of 272 million yuan, with a net profit of 49 million yuan, and a non-recurring net profit of 37 million yuan, reflecting significant growth rates of 25.79%, 81.48%, and 118.80% respectively [6] - The gross margin for the cell culture product business was 71.91%, contributing to an overall gross margin of 56.84% for the first half of 2025 [8] - The company forecasts net profits of 75 million yuan, 102 million yuan, and 133 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.66, 0.89, and 1.17 yuan [6][9] Business Growth and Pipeline - The company has reached a record high in the number of client pipelines, with 311 confirmed drug development pipelines as of September 30, 2025, an increase of 64 from the end of 2024 [7] - The number of projects in commercial production has increased to 13, with a total of 34 in Phase III clinical trials and 60 in Phase I clinical trials [7] Cost Management and Profitability - The company has effectively managed costs, with management expenses decreasing by 34.03% year-on-year, while sales expenses grew by only 5.12%, indicating strong cost control [8] - The net profit margin improved to 20.96%, up 4.38 percentage points year-on-year, reflecting enhanced profitability [8]

上海奥浦迈生物科技股份有限公司 第一章 总则 第四条 独立董事行使下列特别职权： 第一条 为进一步完善上海奥浦迈生物科技股份有限公司（以下简称"公司"） 治理结构，促进公司规范运作，维护公司整体利益，根据《上市公司独立董事管理 办法》《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"） 《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》等国家有关 法律、法规、规范性文件和《上海奥浦迈生物科技股份有限公司章程》（以下简称 "《公司章程》"）的规定，制定本工作制度。 第二条 独立董事专门会议是指全部由公司独立董事参加的会议。 第三条 独立董事对公司及全体股东负有忠实义务与勤勉义务。独立董事应当 按照相关法律法规、《公司章程》和本工作制度的要求，认真履行职责，在董事会 中发挥参与决策、监督制衡、专业咨询作用，维护公司整体利益，保护中小股东合 法权益。 独立董事专门会议工作制度 第二章 职责权限 （一）独立聘请中介机构，对公司具体事项进行审计、咨询或者核查； （六）法律法规、上海证券交易所相关规定及公司章程规定的其他职权。 独立董事行使前款第一项至第三项职权的，应当经全体独立董事过半数同意。 ...

上海奥浦迈生物科技股份有限公司 累积投票制度实施细则 第一章 总则 第一条 为进一步完善上海奥浦迈生物科技股份有限公司（以下简称"公 司"）法人治理结构，规范公司选举董事的行为，维护公司中小股东的利益， 根据《中华人民共和国公司法》等国家有关法律，法规及《上海奥浦迈生物科 技股份有限公司章程》（以下简称"《公司章程》"）等有关规定，特制定本 实施细则。 第二条 本实施细则所称累积投票制是指股东会选举两名以上董事时，股 东所持每一股份拥有与应选出董事人数相等的投票权，股东拥有的投票表决权 总数等于其所持有的股份与应选董事人数的乘积。股东可以按意愿将其拥有的 全部投票表决权集中投向某一位或几位董事候选人，也可以将其拥有的全部投 票表决权进行分配，分别投向各位董事候选人的一种投票制度。 第三条 本实施细则适用于选举或变更两名或两名以上的董事的议案。 第四条 在股东会上拟选举两名或两名以上的董事时，董事会在召开股东 会通知中，表明该次董事的选举采用累积投票制。 第九条 公司董事会收到候选人人选的资料后，应按有关法律、法规和《 公司章程》的规定，认真审核候选人人选的任职资格，经审核合格的候选人人 选成为董事候选人。董事 ...

上海奥浦迈生物科技股份有限公司 独立董事工作制度 第一章 总则 （三）具有经济管理方面高级职称，且在会计、审计或者财务管理等专业 岗位有五年以上全职工作经验。 第二章 独立董事的任职条件 第一条 为进一步完善上海奥浦迈生物科技股份有限公司（以下简称"公 司"）治理结构，促进公司规范运作，维护公司整体利益，根据《中华人民共 和国公司法》（以下简称"《公司法》"）《上市公司治理准则》《上市公司 独立董事管理办法》及《上海证券交易所科创板股票上市规则》《上海证券交 易所科创板上市公司自律监管指引第1号——规范运作》等国家有关法律、法规、 规范性文件和《上海奥浦迈生物科技股份有限公司章程》（以下简称"《公司 章程》"）的规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及主 要股东、实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独 立客观判断关系的董事。 第三条 独立董事对公司及全体股东负有忠实义务、勤勉义务。独立董事 应当按照相关法律法规、《公司章程》及本制度的要求，认真履行职责，在董 事会发挥参与决策、监督制衡、专业咨询作用，维护公司整体利益，保护中小 股东合法权益。 独 ...

上海奥浦迈生物科技股份有限公司 对外担保管理制度 第一章 总则 第一条 为了维护投资者的利益，规范上海奥浦迈生物科技股份有限公司 （以下简称"公司"）的担保行为，控制公司资产运营风险，促进公司健康稳 定地发展，根据《中华人民共和国公司法》《中华人民共和国民法典》（以下 简称"《民法典》"）《上海证券交易所科创板股票上市规则》（以下简称 "《上市规则》"）《上市公司监管指引第8号——上市公司资金往来、对外担 保的监管要求》以及《公司章程》等的相关规定，制定本制度。 第二条 本制度所称担保是指公司以第三人身份为他人提供的保证、抵押、 质押或其他形式的担保。公司及其控股子公司的对外担保总额，是指包括公司 对控股子公司担保在内的公司对外担保总额与控股子公司对外担保之和。 第三条 公司全资子公司和控股子公司对于向上市公司合并报表范围之外的 主体提供担保的，视同公司行为，适用本制度规定。 第四条 公司对外担保实行统一管理，未经公司董事会或股东会批准，公司 及子公司不得对外提供担保，不得相互提供担保，任何人无权以公司名义签署 对外担保的合同、协议或其他类似的法律文件。 第五条 公司董事和高级管理人员应审慎对待和严格控制担保 ...